A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: Evaluation in vitro and in vivo

AAPS PharmSciTech

Volumn 13, Issue 3, 2012, Pages 846-852

  He, Suna ^a,b   Cui, Zheng ^b   Mei, Dong ^b   Zhang, Hua ^b   Wang, Xueqing ^b   Dai, Wenbing ^b   Zhang, Qiang ^a,b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

characterization; pharmacokinetics; self microemulsified drug delivery system; teniposide; tissue distribution

Indexed keywords

ALCOHOL; CREMOPHOR; GLUCOSE; MEDIUM CHAIN TRIACYLGLYCEROL; N,N DIMETHYLACETAMIDE; PHOSPHATIDYLCHOLINE; SURFACTANT; TENIPOSIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DILUTION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG STABILITY; EMULSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; SELF MICROEMULSIFIED DRUG DELIVERY SYSTEM; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; EMULSIFYING AGENTS; FEMALE; INJECTIONS, INTRAVENOUS; MICE; MICE, HAIRLESS; ORGAN CULTURE TECHNIQUES; POLYETHYLENE GLYCOLS; TENIPOSIDE;

EID: 84866116078     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9809-0     Document Type: Article

References (39)

1. McCowage GB, Vowels MR, Shaw PJ, Lockwood L, Mameghan H. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation. J Clin Oncol. 1995;13(11):2789-95.
2. Hayes FA, Abromowitch M, Green AA. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. Cancer Treat Rep. 1985;69(4):439-41.
3. Ruskone-Fourmestraux A, Delmer A, Lavergne A, Molina T, Brousse N, Audouin J, et al. Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D'etude des Lymphomes Digestifs. Gastroenterology. 1997;112(1):7-16.
4. Wang J, Cui Y, Tang X. Chemical stability of teniposide in aqueous and parenteral lipid emulsions. Drug Dev Ind Pharm. 2009;35(4):508-13.
5. Carstensen H, Nolte H, Hertz H. Teniposide-induced hypersensitivity reactions in children. Lancet. 1989;2(8653):55.
6. Nolte H, Carstensen H, Hertz H. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatr Hematol Oncol. 1988;10(4):308-12.
7. Shimizu H, Frankel LS, Culbert SJ. Severe hypertensive reactions to teniposide (VM-26) in infants with congenital leukemia. Am J Pediatr Hematol Oncol. 1987;9(3):239-41.
8. Schwartsmann G, Sprinz E, Kronfeld M, Vinholes J, Sander E, Zampese M, et al. Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma. Eur J Cancer. 1991;27(12):1637-9.
9. Weller M, Müller B, Koch R, Bamberg M, Krauseneck P. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol. 2003;21(17):3276-84.
10. Mañé JM, Fernández R, Muñoz A, Rubio I, Ferreiro J, López-Argumedo G, et al. Preradiation chemotherapy with VM-26 and CCNU in patients with glioblastoma multiforme. Tumori. 2004;90(6):562-6.
11. Gelderblom H, Verweii J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8.
12. Kubisz P, Seghier F, Dobrotora M, Stasko J. Influence of teniposide on platelet functions in vitro. Thromb Res. 1995;77(2):145-8.
13. de Vries EG, Mulder NH, Postmus PE, Vriesendorp R, Willemse PH, Sleijfer DT. High-dose teniposide for refractory malignancies: a phase I study. Cancer Treat Rep. 1986;70(5):595-8.
14. Nornoo AO, Chow DS. Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Int J Pharm. 2008;349(1-2):117-23.
15. Nornoo AO, Osborne DW, Chow DS. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis. Int J Pharm. 2008;349(1-2):108-16.
16. Liliemark E, Sjöström B, Liliemark J, Peterson C, Kållberg N, Larsson BS. Targeting of teniposide to the mononuclear phagocytic system (MPS) by incorporation in liposomes and submicron lipid particles; an autoradiographic study in mice. Leuk Lymphoma. 1995;18(1-2):113-8.
17. Gan L, Gan Y, Zhu C, Zhang X, Zhu J. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int J Pharm. 2009;365(1-2):143-9.
18. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release. 2009;140(2):86-94.
19. Piao HM, Balakrishnan P, Cho HJ, Kim H, Kim YS, et al. Preparation and evaluation of fexofenadine microemulsion for intranasal delivery. Int J Pharm. 2010;395(1-2):309-16.
20. Jogani VV, Shah PJ, Mishra P, Mishra AK, Mishra AR. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord. 2008;22(2):116-24.
21. Li X, Yue Y, Zhou Y, Fan Y, Fan C, Huang Y, et al. An oil-free microemulsion for intravenous delivery of diallyl trisulfide: formulation and evaluation. Int J Pharm. 2011;407(1-2):158-66.
22. Darole PS, Hegde DD, Nair HA. Formulation and evaluation of microemulsion based delivery system for amphotericin B. AAPS PharmSciTech. 2008;9(1):122-8.
23. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173-82.
24. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45(1):89-121.
25. Cao Y, Ni X, Sheng J. Comparison of microstructures of microemulsion and swollen micelle in electrokinetic chromatography. J Chromatogr A. 2011;1218(18):2598-603.
26. Mrestani Y, Behbood L, Albert H, Neubert RHH. Microemulsion and mixed micelle for oral administration as new drug formulations for highly hydrophilic drugs. Eur J Pharm Biopharm. 2010;74(2):219-22.
27. Narang AS, Delmarre D, Gao D. Stable drug encapsulation in micelles and microemulsions. Int J Pharm. 2007;345(1-2):9-25.
28. Nagai N, Shikii T, Mihara K, Ogata H, Sasaki Y. Improved high-performance liquid chromatographic analysis of teniposide in human plasma. J Chromatogr B: Biomed Sci Appl. 1998;709(2):315-9.
29. Sharma G, Wilson K, Walle CF, Sattar N, Petrie JR, Kumar R. Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur J Pharm Biopharm. 2010;76(2):159-69.
30. Liu J, Gong T, Wang CG, Zhong ZR, Zhang ZR. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm. 2007;340(1-2):153-62.
31. Ganta S, Paxton JW, Baguley BC, Garg S. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm. 2008;360(1-2):115-21.
32. Kim SJ, Choi HK, Suh SP, Lee YB. Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion and microsphere formulations in rabbits. Eur J Pharm Sci. 2002;15(5):497-502.
33. Lu Y, Zhang Y, Yang ZY, Tang X. Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm. 2009;366(1-2):160-9.
34. Shi S, Chen H, Lin X, Tang X. Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion. Int J Pharm. 2010;383(1-2):264-70.
35. Henningsson A, Sparreboom A, Sandstrom M, Freijs A, Larsson R, Bergh J, et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer. 2003;39(8):1105-14.
36. Sykes E, Woodburn K, Decker D, Kessel D. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer. 1994;70(3):401-4.
37. Sparreboom A, Zuylen L, Brouwer E, Loos WJ, Bruijn P, Gelderblom M, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59(7):1454-7.
38. Ma HL, Xu YF, Qi XR, Maitani Y, Nagai T. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. Int J Pharm. 2008;354(1-2):217-26.
39. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release. 2004;95(3):613-26.